QT Imaging to Report Third Quarter 2025 Financial Results on November 11 - Webcasted Conference Call to Follow
MWN-AI** Summary
**QT Imaging to Report Third Quarter 2025 Financial Results on November 11**
QT Imaging Holdings, Inc. (OTCQB: QTIH), a pioneering medical device company focused on innovative breast health management solutions, has announced its intention to release its financial results for the third quarter of 2025 after market close on Tuesday, November 11, 2025. Following the financial update, company management will host a live webcasted conference call at 4:30 p.m. ET, providing investors and stakeholders with insights into both the financial results and key business developments.
The call will be accessible to domestic participants at 1-877-545-0523 and international participants at 973-528-0016, using access code 457613. Additionally, the conference call will be streamed live and archived for later access on the company's official website, allowing for broader reach and engagement with stakeholders unable to participate in real-time.
QT Imaging is dedicated to enhancing healthcare outcomes by advancing imaging technologies that prioritize patient safety, affordability, and experience. The company specializes in the research and commercialization of imaging systems utilizing low-frequency sound waves, marking a significant innovation in the medical imaging landscape. With a focus on the Breast Acoustic CT™ technology, QT Imaging aims to transform breast health diagnostics and management.
The release will also address forward-looking statements regarding the company’s growth trajectory, which may include expectations around new product introductions, sales strategies, and market penetration. However, such projections are subject to risks and uncertainties that could significantly affect actual outcomes.
For additional details, potential investors, media representatives, and interested parties are encouraged to visit QT Imaging's website or contact Stephen Kilmer, the Head of Investor Relations.
MWN-AI** Analysis
As QT Imaging Holdings, Inc. prepares to report its third-quarter 2025 financial results on November 11, investors should closely observe several key indicators that may influence the company's stock performance and strategic direction. The conference call following the release will provide invaluable insights into their operations, particularly the ongoing transformation from hardware-focused offerings to a biomarker-driven AI imaging approach. This shift aligns with broader industry trends emphasizing technology integration in healthcare.
Investors should pay particular attention to revenue growth, deployment capabilities of the Breast Acoustic CT technology, and feedback from clinical trials. Markets increasingly prioritize innovative, cost-effective imaging solutions, and QT Imaging's emphasis on radiation-free technology positions it well against competitors focused on traditional imaging modalities. The ability to demonstrate successful commercialization of their products will be crucial in maintaining investor confidence.
Moreover, given QT Imaging's aspiration to expand its product portfolio, updates regarding their pipeline, including potential new applications and partnerships, may influence market sentiment significantly. As they strive to enhance global health outcomes, news about collaborations with healthcare institutions or endorsements from medical bodies could serve as catalysts for share price momentum.
However, it's essential to recognize the inherent risks identified in their forward-looking statements. These range from market trends and competitor actions to operational challenges, which can impact the company's performance. Investors should remain vigilant and consider these risks when evaluating QT Imaging's potential.
Attending the conference call or reviewing the archived version on the company's website could offer clarity on the management's vision and operational strategies, aiding in informed decision-making as QT Imaging navigates the complexities of the medical device landscape in the upcoming quarters.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
QT Imaging Holdings, Inc. (“QT Imaging” or the “Company”) (OTCQB: QTIH), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced that it will release its third quarter 2025 financial results after market close on Tuesday, November 11, 2025. Following the announcement, QT Imaging management will host a webcasted conference call to review the financial results and provide a business update.
Third Quarter 2025 Results Conference Call Details:
Date: | Tuesday, November 11, 2025 | |
Time: | 4:30 p.m. ET | |
Domestic: | 1-877-545-0523 | |
International: | 973-528-0016 | |
Access Code: | 457613 |
The call will also be broadcast live and archived on the Company's website here .
About QT Imaging Holdings, Inc.
QT Imaging Holdings, Inc. is a public (OTCQB: QTIH) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the company’s website at www.qtimaging.com .
Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as “will,” and “expect,” or the negative thereof or comparable terminology, and include (without limitation) statements regarding QT Imaging Breast Acoustic CT imaging technology, plans for QT Imaging Holdings, including its transformation from a hardware-focused startup to a biomarker-driven AI imaging company, new product development and introduction, and product sales growth and projected revenues. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks include, but are not limited to: research results from the use of the QT Imaging Breast Acoustic CT Scanner, the ability of QT Imaging Holdings to sell and deploy the QT Imaging Breast Acoustic CT Scanner, the ability to extend product offerings into new areas or products, the ability to commercialize technology, unexpected occurrences that deter the full documentation and “bring to market” plan for products, trends, and fluctuations in the industry, changes in demand and purchasing volume of customers, unpredictability of suppliers, the ability to attract and retain qualified personnel, and the ability to move product sales to production levels. Additional factors that could cause actual results to differ are discussed under the heading “Risk Factors” and in other sections of QT Imaging Holdings’ filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to QT Imaging Holdings as of the date hereof, and QT Imaging Holdings assumes no obligation to update any forward-looking statement.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251104356935/en/
For media inquiries, please contact:
Stephen Kilmer
Head of Investor Relations
Stephen.Kilmer@qtimaging.com
Direct: (646) 274-3580
FAQ**
How does QT Imaging Holdings, Inc. (QTIH) plan to overcome the risks associated with selling and deploying its Breast Acoustic CT Scanner in the current medical device market?
What specific new product developments can investors expect from QT Imaging Holdings (QTIH) in the upcoming quarters, considering its focus on transforming into a biomarker-driven AI imaging company?
In light of the company's strategy to improve global health outcomes, how does QT Imaging Holdings (QTIH) ensure that its imaging technology remains affordable and accessible to patients?
Considering the projected revenues mentioned in the press release, what metrics and timelines will QT Imaging Holdings (QTIH) use to evaluate the success of its product sales growth in the near future?
**MWN-AI FAQ is based on asking OpenAI questions about QT Imaging Holdi (OTC: QTIH).
NASDAQ: QTIH
QTIH Trading
-3.39% G/L:
$5.70 Last:
887 Volume:
$6 Open:
